Editas Medicine, Inc. (EDIT) vs Neurogene Inc. (NGNE)
A side-by-side comparison of Editas Medicine, Inc. and Neurogene Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EDIT
Editas Medicine, Inc.
$2.83HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
NGNE
Neurogene Inc.
$26.10HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
Total return — EDIT vs NGNE
growth of $100 · dividends reinvested · last 10yEDIT -81.4% (-15.5%/yr)NGNE -90.2% (-20.8%/yr)EDIT compounded faster over this window
EDIT NGNE
EDIT vs NGNE: by the numbers
- •EDIT is the larger company ($434M vs $412M market cap).
- •Both run net losses; NGNE's is the smaller (0.00% vs -157.32% net margin).
Metrics side by side
Valuation
| Metric | EDIT | NGNE |
|---|---|---|
| P/S ratio | 9.22 | N/A |
| P/B ratio | 4.12 | 1.90 |
Profitability
| Metric | EDIT | NGNE |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -245.15% | 0.00% |
| Net margin | -157.32% | 0.00% |
| ROE | -70.24% | -51.17% |
| ROIC | -48.61% | -54.45% |
Growth (annualized)
| Metric | EDIT | NGNE |
|---|---|---|
| Revenue CAGR (5Y) | -10.34% | N/A |
| Total return CAGR (5Y) | -40.76% | -27.73% |
Frequently asked
- How have EDIT and NGNE total returns compared?
- Over the past 10 years, EDIT delivered -15.75% and NGNE delivered -21.02% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.